204 related articles for article (PubMed ID: 15861006)
21. Weighing in on molecular anchors: the role of ankyrin polypeptides in human arrhythmia.
Kline CF; Mohler PJ
Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):477-85. PubMed ID: 16918266
[TBL] [Abstract][Full Text] [Related]
22. A Novel Mechanism for Human Cardiac Ankyrin-B Syndrome due to Reciprocal Chromosomal Translocation.
Huq AJ; Pertile MD; Davis AM; Landon H; James PA; Kline CF; Vohra J; Mohler PJ; Delatycki MB
Heart Lung Circ; 2017 Jun; 26(6):612-618. PubMed ID: 27916589
[TBL] [Abstract][Full Text] [Related]
23. Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes.
Mohler PJ; Le Scouarnec S; Denjoy I; Lowe JS; Guicheney P; Caron L; Driskell IM; Schott JJ; Norris K; Leenhardt A; Kim RB; Escande D; Roden DM
Circulation; 2007 Jan; 115(4):432-41. PubMed ID: 17242276
[TBL] [Abstract][Full Text] [Related]
24. Dysfunction in the βII spectrin-dependent cytoskeleton underlies human arrhythmia.
Smith SA; Sturm AC; Curran J; Kline CF; Little SC; Bonilla IM; Long VP; Makara M; Polina I; Hughes LD; Webb TR; Wei Z; Wright P; Voigt N; Bhakta D; Spoonamore KG; Zhang C; Weiss R; Binkley PF; Janssen PM; Kilic A; Higgins RS; Sun M; Ma J; Dobrev D; Zhang M; Carnes CA; Vatta M; Rasband MN; Hund TJ; Mohler PJ
Circulation; 2015 Feb; 131(8):695-708. PubMed ID: 25632041
[TBL] [Abstract][Full Text] [Related]
25. Common human ANK2 variant confers in vivo arrhythmia phenotypes.
Musa H; Murphy NP; Curran J; Higgins JD; Webb TR; Makara MA; Wright P; Lancione PJ; Lubbers ER; Healy JA; Smith SA; Bennett V; Hund TJ; Kline CF; Mohler PJ
Heart Rhythm; 2016 Sep; 13(9):1932-40. PubMed ID: 27298202
[TBL] [Abstract][Full Text] [Related]
26. Ankyrin-B regulates Kir6.2 membrane expression and function in heart.
Li J; Kline CF; Hund TJ; Anderson ME; Mohler PJ
J Biol Chem; 2010 Sep; 285(37):28723-30. PubMed ID: 20610380
[TBL] [Abstract][Full Text] [Related]
27. Defects in ankyrin-based membrane protein targeting pathways underlie atrial fibrillation.
Cunha SR; Hund TJ; Hashemi S; Voigt N; Li N; Wright P; Koval O; Li J; Gudmundsson H; Gumina RJ; Karck M; Schott JJ; Probst V; Le Marec H; Anderson ME; Dobrev D; Wehrens XH; Mohler PJ
Circulation; 2011 Sep; 124(11):1212-22. PubMed ID: 21859974
[TBL] [Abstract][Full Text] [Related]
28. Dysfunction in ankyrin-B-dependent ion channel and transporter targeting causes human sinus node disease.
Le Scouarnec S; Bhasin N; Vieyres C; Hund TJ; Cunha SR; Koval O; Marionneau C; Chen B; Wu Y; Demolombe S; Song LS; Le Marec H; Probst V; Schott JJ; Anderson ME; Mohler PJ
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15617-22. PubMed ID: 18832177
[TBL] [Abstract][Full Text] [Related]
29. Defining a new paradigm for human arrhythmia syndromes: phenotypic manifestations of gene mutations in ion channel- and transporter-associated proteins.
Ackerman MJ; Mohler PJ
Circ Res; 2010 Aug; 107(4):457-65. PubMed ID: 20724725
[TBL] [Abstract][Full Text] [Related]
30. Ankyrin-B is required for intracellular sorting of structurally diverse Ca2+ homeostasis proteins.
Tuvia S; Buhusi M; Davis L; Reedy M; Bennett V
J Cell Biol; 1999 Nov; 147(5):995-1008. PubMed ID: 10579720
[TBL] [Abstract][Full Text] [Related]
31. Ankyrin-B syndrome: a case of sinus node dysfunction, atrial fibrillation and prolonged QT in a young adult.
Robaei D; Ford T; Ooi SY
Heart Lung Circ; 2015 Feb; 24(2):e31-4. PubMed ID: 25456501
[TBL] [Abstract][Full Text] [Related]
32. Conditional knockout of Fgf13 in murine hearts increases arrhythmia susceptibility and reveals novel ion channel modulatory roles.
Wang X; Tang H; Wei EQ; Wang Z; Yang J; Yang R; Wang S; Zhang Y; Pitt GS; Zhang H; Wang C
J Mol Cell Cardiol; 2017 Mar; 104():63-74. PubMed ID: 28119060
[TBL] [Abstract][Full Text] [Related]
33. Subcellular distribution of ankyrin in developing rabbit heart--relationship to the Na+-Ca2+ exchanger.
Chen F; Mottino G; Shin VY; Frank JS
J Mol Cell Cardiol; 1997 Oct; 29(10):2621-9. PubMed ID: 9344757
[TBL] [Abstract][Full Text] [Related]
34. Disruption of Ankyrin B and Caveolin-1 Interaction Sites Alters Na
Junghans C; Vukojević V; Tavraz NN; Maksimov EG; Zuschratter W; Schmitt FJ; Friedrich T
Biophys J; 2017 Nov; 113(10):2249-2260. PubMed ID: 28988699
[TBL] [Abstract][Full Text] [Related]
35. Intracellular calcium attenuates late current conducted by mutant human cardiac sodium channels.
Potet F; Beckermann TM; Kunic JD; George AL
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):933-41. PubMed ID: 26022185
[TBL] [Abstract][Full Text] [Related]
36. Protein 4.1 and the control of ion channels.
Baines AJ; Bennett PM; Carter EW; Terracciano C
Blood Cells Mol Dis; 2009; 42(3):211-5. PubMed ID: 19272819
[TBL] [Abstract][Full Text] [Related]
37. Molecular basis for PP2A regulatory subunit B56alpha targeting in cardiomyocytes.
Bhasin N; Cunha SR; Mudannayake M; Gigena MS; Rogers TB; Mohler PJ
Am J Physiol Heart Circ Physiol; 2007 Jul; 293(1):H109-19. PubMed ID: 17416611
[TBL] [Abstract][Full Text] [Related]
38. The ankyrin-B C-terminal domain determines activity of ankyrin-B/G chimeras in rescue of abnormal inositol 1,4,5-trisphosphate and ryanodine receptor distribution in ankyrin-B (-/-) neonatal cardiomyocytes.
Mohler PJ; Gramolini AO; Bennett V
J Biol Chem; 2002 Mar; 277(12):10599-607. PubMed ID: 11781319
[TBL] [Abstract][Full Text] [Related]
39. CaMKII inhibition rescues proarrhythmic phenotypes in the model of human ankyrin-B syndrome.
DeGrande S; Nixon D; Koval O; Curran JW; Wright P; Wang Q; Kashef F; Chiang D; Li N; Wehrens XH; Anderson ME; Hund TJ; Mohler PJ
Heart Rhythm; 2012 Dec; 9(12):2034-41. PubMed ID: 23059182
[TBL] [Abstract][Full Text] [Related]
40. Obscurin targets ankyrin-B and protein phosphatase 2A to the cardiac M-line.
Cunha SR; Mohler PJ
J Biol Chem; 2008 Nov; 283(46):31968-80. PubMed ID: 18782775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
